Clinical Trial Update: 18F-Fluoromisonidazole and Fludeoxyglucose F 18 PET/CT Patients With Soft Tissue Sarcoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating PET/CT using 18F-fluoromisonidazole and 18F-fludeoxyglucose in soft tissue sarcoma was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Soft Tissue Sarcoma

Drugs mentioned

• 18F-Fludeoxyglucose (fluorodeoxyglucose F-18)
• 18F-Fluoromisonidazole (18F-fluoromisonidazole)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Adult Soft Tissue Sarcoma, Stage I Adult Soft Tissue Sarcoma | Phase 2 | Status: TERMINATED | Results posted: 2017-11-17